Abstract: A system, apparatus, and method using carbon monoxide for treatment of platelets, and optionally other blood components and/or whole blood, allowing extended storage and increased viability of the stored blood platelets in vivo. The system allows an efficient use of the stored platelets by dividing the platelets into a population with a short residual lifetime for immediate use and a population that can remain in storage for longer. The storage apparatus enables safe platelet preservation and is equipped with an alarm to detect CO leakage.

Abstract: A method for inhibiting bacterial growth in whole blood and/or blood components, which may therefore also be used to extend the storage time for the whole blood and/or blood components, through treatment with carbon monoxide. This method is preferably used for the preservation of platelets, which are both particularly vulnerable to bacterial and other microbial infection, and which are also particularly suitable for use with the method of the present invention. Carbon monoxide may be present in an amount of from about 40% to about 100%. Platelets may be stored in a solution buffered by any suitable buffer, such as sodium bicarbonate. Platelet viability may be determined by measuring the ability to aggregate, for example in response to an agonist such as collagen.

Abstract: A method for inhibiting bacterial growth in whole blood and/or blood components, which may therefore also be used to extend the storage time for the whole blood and/or blood components, through treatment with carbon monoxide. This method is preferably used for the preservation of platelets, which are both particularly vulnerable to bacterial and other microbial infection, and which are also particularly suitable for use with the method of the present invention. Carbon monoxide may be present in an amount of from about 40% to about 100%. Platelets may be stored in a solution buffered by any suitable buffer, such as sodium bicarbonate. Platelet viability may be determined by measuring the ability to aggregate, for example in response to an agonist such as collagen.

Abstract: This invention relates to novel methods of increasing the level of fetal hemoglobin (HbF) in a subject and methods of treating, preventing or ameliorating .beta.-globin or other HbF-related disorders by increasing the level of HbF in a subject in need of such treatment comprising administering one or more compounds of the Formulae (I), (II), or (III):(I) XCH.sub.2 --CHX--CHX--C(.dbd.O)--O--Z(II) CH.sub.3 --CO--CH.sub.2 --C(.dbd.O)--O--Z(III) CH.sub.3 --CH.sub.2 --CO--C(.dbd.O)--O--Zwherein:X is H, or one of X only may be OH;Z is --CHR--O--C(.dbd.O)R', --CHR--O--C(.dbd.